Why Metabolic Health Is the Foundation of Safe, Effective Hormone Therapy

The Whole-Person Approach: Why We Assess Before We Prescribe

Before starting any hormone therapy — estrogen, progesterone, or testosterone — we evaluate the full metabolic picture. This includes inflammatory markers, insulin sensitivity, lipid profiles, micronutrient status, and in some cases, genetic testing. Here's why each matters.

Inflammation Changes How Your Body Processes Hormones

When chronic inflammation is present — from metabolic syndrome, poor sleep, excess visceral fat, or insulin resistance — the body's hormone-processing enzymes shift in ways that can make hormone therapy less effective or even counterproductive.

One key enzyme, COMT (catechol-O-methyltransferase), is responsible for safely clearing estrogen breakdown products from the body and brain. Neuroinflammation has been shown to impair COMT function, allowing reactive estrogen byproducts to accumulate rather than being neutralized. Another enzyme, CYP1B1, converts estrogen into byproducts that require COMT to clear them. When inflammation pushes CYP1B1 up while impairing COMT, those reactive compounds can build up where they shouldn't — including in brain tissue.

Put plainly: the same prescription can land very differently depending on the metabolic terrain it enters. That's why we look at the terrain first.

The Brain Connection: Estrogen, Amyloid, and the Tipping Point

Estrogen is deeply neuroprotective — but the effect depends on the state of the brain receiving it. Research on the "healthy cell bias" has shown that estrogen supports mitochondrial function, promotes amyloid-beta clearance, and enhances synaptic plasticity in healthy neurons. In neurons that are already stressed by amyloid accumulation, oxidative stress, or mitochondrial dysfunction, the same signal interacts with a different system — and the response can be less predictable.

Inside the brain, a mitochondrial enzyme called 17β-HSD type 10 normally helps maintain neurosteroid balance. When amyloid-beta accumulates, it binds to this enzyme and disrupts mitochondrial regulation. That ties the brain's estrogen handling to its broader inflammatory and metabolic state — which is part of why "the right hormone" depends so much on the body it's entering.

This is why timing matters in the research. Starting hormone therapy early — within 5 to 10 years of menopause, before these cascades take hold — has been associated with cognitive protection in several lines of evidence. Starting much later, when the underlying terrain has already shifted, produces more uncertain effects, which is why timing, formulation, and individual context all come into the conversation.

For a deeper look at the trials and the debate behind the timing question, see our companion article on the critical window hypothesis.

Genetics: Why the Same Hormone Affects People Differently

Two genetic tests can meaningfully inform hormone therapy decisions:

Men and Testosterone: The Same Principles Apply

In men, the relationship between metabolic health and hormones is equally important — and often overlooked. Testosterone deficiency and metabolic syndrome exist in a vicious cycle: low testosterone promotes visceral fat accumulation and insulin resistance, while obesity and metabolic dysfunction suppress testosterone production through increased aromatization (conversion of testosterone to estrogen in fat tissue), elevated inflammatory mediators, and reduced gonadotropin secretion.

Many men presenting with "low testosterone" actually have functional hypogonadism driven by metabolic dysfunction. Research has shown that weight loss alone can restore testosterone levels in a substantial percentage of these men, without requiring lifelong testosterone replacement. When metabolic health is addressed first — through nutrition, exercise, sleep optimization, and management of insulin resistance — some men find they no longer need testosterone therapy at all.

For men who do have true hypogonadism requiring treatment, metabolic optimization still matters. Excess aromatase activity in visceral fat converts supplemental testosterone into estrogen, potentially shifting signaling toward pro-inflammatory estrogen receptor alpha pathways — the same problematic pattern seen in women with metabolic syndrome on estrogen therapy.

Our Approach: Optimize First, Then Personalize

Rather than simply prescribing hormones based on symptoms alone, we take a systematic approach:

The Bottom Line

Hormones are powerful tools, but they work best in a healthy system. Whether the goal is managing menopausal symptoms, protecting long-term brain and bone health, or optimizing testosterone in men, metabolic health is the foundation that determines whether hormone therapy delivers its full benefits safely.

A whole-person approach — addressing inflammation, nutrition, genetics, and lifestyle alongside hormones — is not just good medicine. It's the difference between hormones that heal and hormones that may inadvertently cause harm.

Frequently Asked Questions